Latest Telaprevir Stories
LONDON, December 17, 2014 /PRNewswire/ -- Report Details Hepatitis C treatments - your guide to medical needs, R&D trends and future drug revenues Discover
- Major regulatory milestone achieved toward approval in the European Union NORTH CHICAGO, Ill., Nov.
MarketOptimizer.org adds “PharmaPoint: Hepatitis C Virus – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store.
San Antonio researcher leads national study that identified a combination of pills that cures 9 of 10 hepatitis C patients. San Antonio, TX (PRWEB) July 29,
Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat.
The Majority of Surveyed Primary Care Physicians Expect to Refer HCV Patients to a Specialist for Care, According to Findings from Decision Resources Group BURLINGTON, Mass., June 19, 2014
NORTH CHICAGO, Ill., June 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the
-- Filing Includes Data from Treatment-Naive Patients with Advanced Fibrosis and Null Responders with All Stages of Liver Fibrosis -- RARITAN, N.J., May 7, 2014 /PRNewswire/ -- Janssen Research
The new interferon-free, all-oral, three direct-acting-antiviral (3D) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected with hepatitis C virus (HCV) genotype 1 (GT1); according to the results of three studies presented today at the International Liver CongressTM 2014.
LONDON, April 12, 2014 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced new results from cohort 2 of the Phase 2 COSMOS study demonstrating that 93 percent of patients with
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.